Buccolam: licensed buccal midazolam product

Buccal midazolam is now available as a licensed product (Buccolam) for paediatric use.

Buccolam is available in four colour-coded pre-filled oral syringes, each suitable for different age groups
Buccolam is available in four colour-coded pre-filled oral syringes, each suitable for different age groups

Buccolam is approved for the treatment of prolonged acute convulsive seizures in children aged between 3 months and 18 years of age.

For infants between 3 and 6 months of age, treatment should be provided under the supervision of a healthcare professional in a hospital setting where resuscitation equipment is available.

First paediatric use marketing authorisation

Buccolam is the first medicine to be approved under the Paediatric Use Marketing Authorisation (PUMA) procedure. The aim of the PUMA process is to encourage research into the use of existing medicines in children by affording the same exclusivity rights as completely new medicines. It was introduced in an attempt to reduce the widespread off-label use of drugs in children.

In 4 studies using rectal diazepam as control, buccal midazolam was effective in stopping seizures within 10 minutes in 65% to 78% of children compared with 41% to 85% of children for rectal diazepam.

Switching issues

The Medicines and Healthcare products Regulatory Agency Drug Safety Update (October 2011) has highlighted safety issues for consideration when switching patients from unlicensed products to the licensed product, including noting that Buccolam is half the strength of some other unlicensed products.

Although there is some suggestion that the maleate salt used in some other products is better absorbed by buccal adminstration, there are adequate studies to support the licensed doses of Buccolam, which contains midazolam hydrochloride.
    
MHRA Drug Safety update – October 2011

View Buccolam drug record

Further information: ViroPharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...